Latest news with #CRISPR
Associated Press
2 days ago
- Health
- Associated Press
Novartis, BrainStorm Cell Therapeutics, Neuroplast, Rapa Therapeutics, and Longeveron Driving Innovations
DUBLIN--(BUSINESS WIRE)--Jun 27, 2025-- The 'Gene and Cell Therapies Targeting CNS Disorders Market - A Global and Regional Analysis: Focus on Drug and Region - Analysis and Forecast, 2025-2035" report has been added to offering. Global gene and cell therapies targeting central nervous system (CNS) disorders a market is on track for continued growth, driven by the aging population, and the development of more effective and comfortable solutions. The ongoing advancements in product technology and the expansion of care options will continue to shape the market's future. As demand for gene and cell therapies targeting central nervous system (CNS) disorders therapies rises, both global and regional players will play a key role in meeting the needs of individuals and healthcare systems alike, improving quality of life for people living with incontinence. The gene and cell therapies targeting central nervous system (CNS) disorders are rapidly advancing, offering potential treatments for conditions such as Parkinson's, Alzheimer's, Huntington's disease, and spinal cord injuries. Increasing incidences of CNS disorders one of the major driving factors of this market. The increasing number of patients with neurological disorders such as Alzheimer's, Parkinson's, and multiple sclerosis is creating an urgent need for innovative treatments. This drives demand for gene and cell therapies, as current treatments are often ineffective or only offer temporary relief. One of the significant drivers of the global gene and cell therapies targeting central nervous system (CNS) disorders market is the technological advancements in treatment delivery. The technological innovations in drug delivery systems, such as CRISPR and gene editing, stem cell therapy and AAV vectors for gene delivery. Furthermore, improved precision in treatment technologies such as CRISPR-Cas9 allow for precise editing of genes involved in neurological diseases. This level of precision offers hope for conditions that have a genetic root, such as Huntington's disease or spinal muscular atrophy have contributed to the market's growth. Despite the growth trajectory, several challenges continue to impact the global gene and cell therapies targeting central nervous system (CNS) disorders market. One of the primary challenges is high development and manufacturing costs. The developing and manufacturing gene and cell therapies, especially those targeting CNS disorders, is extremely expensive. The production of viral vectors for gene delivery and the preparation of cell-based therapies are both costly and complex processes. The high costs of developing these therapies can limit accessibility and affordability for patients. Additionally, these high costs can result in delayed market entry and restrictions on patient access, particularly in low- and middle-income countries. Leading players in the global gene and cell therapies targeting central nervous system (CNS) disorders market, such as Novartis, and BrainStorm Cell Therapeutics are continuously innovating to improve the effectiveness and comfort of gene and cell therapies targeting central nervous system (CNS) disorders. These companies are investing heavily in research and development to introduce new, technologically advanced therapies into the market. With a strong emphasis on user-friendly and environmentally sustainable products, these companies are shaping the future of gene and cell therapies targeting central nervous system (CNS) disorders while enhancing their market positions globally. The competitive landscape of the global gene and cell therapies targeting central nervous system (CNS) disorders market is diverse, with numerous players across different regions offering a wide range of products. Regional players and local manufacturers are expected to play an important role in the market's growth, especially as demand increases in emerging markets such as Asia-Pacific. As consumer preferences shift towards more discreet, comfortable, and affordable solutions, the gene and cell therapies targeting central nervous system (CNS) disorders market will continue to evolve, fostering new opportunities for both established and emerging companies. As the gene and cell therapies targeting central nervous system (CNS) disorders market evolves, emerging trends such expansion of cell-based therapies and focuses on personalized or precision medicine. This trend allows treatments to be more specific and effective for individual patients, reducing side effects and improving patient outcomes. Companies Featured Key Topics Covered: Executive Summary 1. Global Gene and Cell Therapies Targeting CNS Disorders Market: Industry Outlook 1.1 Overview 1.2 Regulatory Landscape 1.3 Global Gene and Cell Therapies Targeting CNS Disorders Market, Patent Landscape 1.3.1 By Country 1.3.2 By Year 1.4 Global Gene and Cell Therapies Targeting CNS Disorders Market, Clinical Trials Landscape 1.5 Key Trends 1.6 Market Dynamics 1.6.1 Overview 1.6.1.1 Impact Analysis 1.6.2 Market Drivers 1.6.3 Market Restraints 1.6.4 Market Opportunities 2. Global Gene and Cell Therapies Targeting CNS Disorders Market, by Drugs, $Million, 2023-2035 2.1 Gene Therapy Drugs 2.2 Cell Therapy Drugs 3. Global Gene and Cell Therapies Targeting CNS Disorders, by Region, $Million, 2023-2035 3.1 North America 3.1.1 Key Findings in North America 3.1.2 Market Dynamics 3.1.3 Market Sizing and Forecast 3.1.3.1 North America Gene and Cell Therapies Targeting CNS Disorders Market, By Country 3.1.3.1.1 U.S. 3.1.3.1.2 Canada 3.2 Europe 3.2.1 Key Findings in Europe 3.2.2 Market Dynamics 3.2.3 Market Sizing and Forecast 3.2.3.1 Europe Gene and Cell Therapies Targeting CNS Disorders Market, By Country 3.2.3.1.1 Germany 3.2.3.1.2 U.K. 3.2.3.1.3 France 3.2.3.1.4 Italy 3.2.3.1.5 Spain 3.2.3.1.6 Rest-of-Europe 3.3 Asia-Pacific 3.3.1 Key Findings in Asia-Pacific 3.3.2 Market Dynamics 3.3.3 Market Sizing and Forecast 3.3.3.1 Asia-Pacific Gene and Cell Therapies Targeting CNS Disorders Market, By Country 3.3.3.1.1 Japan 3.3.3.1.2 China 3.3.3.1.3 India 3.3.3.1.4 Rest-of-Asia-Pacific 3.4 Rest-of-the-World 3.4.1 Key Findings in Rest-of-the-World 3.4.2 Market Dynamics 3.4.3 Market Sizing and Forecast 4. Global Gene and Cell Therapies Targeting CNS Disorders Market: Competitive Landscape and Company Profiles 4.1 Competitive Landscape 4.1.1 New Offerings 4.1.2 Mergers and Acquisitions 4.1.3 Partnerships, Alliances, and Business Expansion 4.1.4 Funding Activities 4.1.5 Regulatory Approvals 4.2 Company Profiles 4.2.1 Overview 4.2.2 Product Portfolio 4.2.3 Target Customers 4.2.4 Key Professionals 4.2.5 Analyst View 5. Research Methodology For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. View source version on CONTACT: Laura Wood, Senior Press Manager [email protected] For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 KEYWORD: INDUSTRY KEYWORD: GENERAL HEALTH NEUROLOGY HEALTH GENETICS PHARMACEUTICAL SOURCE: Research and Markets Copyright Business Wire 2025. PUB: 06/27/2025 09:33 AM/DISC: 06/27/2025 09:33 AM
Time Magazine
2 days ago
- Business
- Time Magazine
TIME100 Most Influential Companies 2025: Vertex Pharmaceuticals
Boston and London biotech company Vertex Pharmaceuticals is on a roll. In the past year and a half, Vertex worked with CRISPR Therapeutics to develop the first CRISPR treatment approved by the U.S. FDA, called Casgevy, which treats sickle-cell disease and beta thalassemia; received approval for its fifth cystic fibrosis treatment, and in January, also earned FDA approval for the first non-opioid pain killer, Journavx, in more than two decades. CEO Dr. Reshma Kewalramani is a triple threat, combining medical, research, and business experience to lead the 36-year-old company. She has continued the drug development pathway on which the company was founded: rational drug design, meaning designing drugs to address a known biological process, rather than spending time with the traditional trial and error practice of combining and testing chemicals in the hope of landing on one that has the desired effect. When faced with the myriad diseases and equally numerous targets for potential drugs the company could pursue, Kewalramani leans on a specific formula: Vertex concentrates on diseases where there aren't many treatment options, or high unmet need; they look for genetic or drug targets that animal models show can make a difference in the disease; the disease needs to have so-called biomarkers, or ways that researchers can track changes produced by the treatment; and the therapy developed should have a clear pathway for getting approval from regulatory agencies like the FDA. The approach has served the company well. Its market capitalization is around $114 billion, and total revenues were up 12% from the previous year. Treating pain in a way that avoided the addictive side effect of opioids checked all of these boxes, although it took two decades to identify the right pathway to target. 'Why did we do this? Because we thought pain was an incredibly important disease where there was no innovation and where we thought we could make a big difference,' says Kewalramani. 'And why did we keep going? Because of the science and our desire to work in areas where we could make this kind of transformative leap.' Following the launch of Casgevy, which allows people with sickle cell disease to receive a single CRISPR gene therapy to address the genetic mutation responsible for their disease, Vertex is continuing to pursue what Kewalramani calls 'one and done curative medicines.' They are in the late stages of testing a cell-based treatment for type 1 diabetes that could potentially help people skip regular insulin injections by giving them healthy insulin-making pancreatic beta cells. The company is also developing new treatments for chronic kidney disease, for which there have not been new options in almost a decade, and in 2024, Vertex bought Alpine Immune Sciences for $4.9 billion to accelerate its search for novel kidney treatments. 'We are simply not interested in making me-too medicines,' says Kewalramani.
Yahoo
3 days ago
- Science
- Yahoo
Scientists Edited Sperm to Bypass an Egg. The Result? A Mouse With Two Dads.
"Hearst Magazines and Yahoo may earn commission or revenue on some items through these links." Here's what you'll learn when you read this story: The first mice to be created from two fathers, a phenomenon known as androgenesis, have now produced healthy offspring for the first time. Researchers implanted two sperm in an egg with its nucleus removed and modified the sperm with epigenome editing, turning certain genes on and off. This process carries a high risk, but it could be used for human reproduction and saving endangered species in the future. Millions of years of evolution have determined how mammals reproduce, but if something doesn't occur in nature, it is not necessarily impossible. It could still be achieved in a lab. Mammalian reproduction usually needs one sperm and one oocyte (egg) to create a zygote that develops in the womb until it becomes a new organism. Embryogenesis and fetal development in mice and humans are similar, which is why mice are often used as prototypes for human experiments. Also like humans, mice, at least on their own, cannot create a viable zygote out of two eggs or two sperm. That is where genetic intervention comes in. Earlier this year, researcher Yanchang Wei at Shanghai Jiao Tong University in China succeeded at creating mouse embryos from two sperm cells that were implanted into an egg after its nucleus had been removed. Giving the embryo a chance at survival meant making alterations to seven sites in the sperm DNA. The embryos grew inside surrogate mothers, but only two of over two hundred made it to adulthood. Those two mice have now reproduced successfully, showing that it is possible for at least one kind of mammal with two biological fathers to have healthy offspring of its own. 'Mammals are diploid creatures,' Wei said in a study recently published in PNAS. 'Every cell in their body contains two sets of chromosomes, one from the mother and one from the father. Mouse embryos with only paternal genomes can not develop to term, even being diploid (with two sets of chromosomes).' Behind what appears to be a miracle is a method known as epigenome editing. Because the epigenome is made up of chemical compounds that give the genome directions by modifying it, the process involves editing proteins, DNA and RNA at specific locations in the genome. There is no actual change to the genome made in epigenome editing, just a shift in which genes receive chemical signals to activate or inactivate them. There are some genes in sperm and eggs that are automatically switched on or off. Wei and his team used modified CRISPR proteins to turn on genes in the sperm cells that eggs would have normally had turned on. Androgenesis is rare among animals. While its does occur among some species of invertebrates, amphibians and fish. This phenomenon can happen when females produce eggs without a nucleus, which are then fertilized by males. The embryos will only inherit the genes of their father. In another type of androgenesis, both a sperm and egg form a zygote, but the genome of the female is eliminated. Males essentially use the eggs to clone themselves. It is thought that (with the exception of hermaphroditic organisms such as clams) androgenesis did not evolve much because the population would be dominated by male genes to the point of extinction. Creating mice from two mothers is easier in comparison. Known as parthenogenesis or 'virgin birth,' this phenomenon has been seen in reptiles, amphibians, insects, fish and even California condors. In 2004, a Japanese research team succeeded in genetically modifying and birthing the first fertile parthenogenic mouse, Kaguya. Whether genetically modified androgenesis or parthenogenesis will succeed in humans remains to be seen. The high risk is currently prohibitive. In the future, it might be a viable option, and could also be used to save critically endangered species which may only have a few individuals of one sex remaining. Never say 'impossible.' You Might Also Like The Do's and Don'ts of Using Painter's Tape The Best Portable BBQ Grills for Cooking Anywhere Can a Smart Watch Prolong Your Life?
Arabian Post
3 days ago
- Business
- Arabian Post
ADQ Stakes Ambition on Climate-Smart Vegetable Seeds
Abu Dhabi sovereign investor ADQ is negotiating the acquisition of a 35 percent stake in Limagrain's vegetable seeds unit, forging a strategic partnership focused on developing hard‑climate‑resilient crops. The envisioned alliance includes joint research and development initiatives in the UAE, designed to accelerate innovation in seeds tailored to extreme conditions. The proposed investment centres on Limagrain Vegetable Seeds, the vegetable‑seed division of France‑based cooperative Limagrain, a global market leader boasting €796 million in sales for the 2023–24 financial year. ADQ's entry through its agritech subsidiary Silal would create a joint venture operating from Al Ain's Innovation Oasis. The hub features facilities for controlled‑environment testing—greenhouses, growth chambers and seed‑testing labs. Under the agreement, the research partnership will focus on non‑GMO approaches such as gene editing and selective breeding to enhance vegetable species—tomatoes, cucumbers, melons—against heat, drought and salinity. ADQ has emphasised its role aligns with the UAE's National Food Security Strategy 2051, which aims to raise domestic food output to 50 percent of consumption. Currently, as much as 90 percent of the UAE's food is imported. ADVERTISEMENT Limagrain's CEO, Sébastien Chauffaut, described ADQ as 'a likeminded partner' sharing a long‑term commitment to sustainable investment and innovation. He noted the venture would both strengthen LVS's global leadership and increase access to Middle East and North Africa markets. For ADQ, the move represents a strategic expansion deeper into the food‑agriculture sector. Its track record includes a 45 percent stake in Louis Dreyfus Company, one of the world's largest crop merchants. Mansour Al Mulla, ADQ's Deputy CEO, emphasised that entering the seed space was a logical extension of its existing food‑chain investments, aligning with national economic resilience goals. Experts highlight seed innovation as a key lever in addressing climate volatility. Antonios Vouloudis of NYU Abu Dhabi notes that desert‑adapted seed development is crucial for expanding agriculture in arid zones, complementing controlled‑environment farming. Gene‑editing tools like CRISPR are identified as enablers of targeted improvements without introducing foreign genes—thus sidestepping GMO regulatory hurdles. The global market for climate‑smart seeds is expected to surpass US $15 billion by 2030, driven by rising demand in regions vulnerable to extreme climates. ADQ and Limagrain aim for the collaboration's scope to extend beyond the UAE, positioning their desert‑resilient seed offerings to agriculture sectors in Africa, southern Europe and Central America. Should the investment close—subject to regulatory clearance and employee consultations—ADQ would secure representation on LVS's board with a 35 percent equity share. Limagrain would retain management control while ADQ gains significant influence over strategic direction and R&D policy. Timeline projections from ADQ suggest a deal completion by year‑end, followed by breeding trials in controlled environments and field tests. Promising varieties are expected to reach commercial agriculture within one to two years. Initial testing will occur in Silal's Al Ain infrastructure, with farmer integration following proof‑of‑concept success. Limagrain brings to the table its extensive genetic‑improvement capabilities, spanning 56 research centres globally and support of 43 major vegetable crops. Brands under its umbrella include Vilmorin, Mikado, Harris Moran, Clause and Hazera, serving growers across Europe, the Americas, Asia and the Middle East. Water management poses another strategic focus. Agriculture uses about 60 percent of the UAE's water, with groundwater levels falling by around one metre yearly in some regions. Improved seed efficiency could reduce irrigation demand, increasing per‑hectare yields and lowering costs for consumers. However, success hinges on navigating regulatory environments, scaling technologies, and competing with global seed firms such as Bayer and Syngenta. Gene‑editing remains controversial in some regions, despite being distinct from GMO interventions. For ADQ, linking cutting‑edge agricultural tech with national food‑security objectives represents both economic foresight and a blueprint for global scalability. By combining genetic science from Limagrain with infrastructure and funding from the UAE, the partnership aspires to transform desert agriculture and reinforce food resilience in the face of climate pressures.
Yahoo
3 days ago
- Business
- Yahoo
[Latest] Global Cell and Gene Therapy Market Size/Share Worth USD 118.63 Billion by 2034 at a 18.79% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis)
[220+ Pages Latest Report] According to a market research study published by Custom Market Insights, the demand analysis of Global Cell and Gene Therapy Market size & share revenue was valued at approximately USD 21.23 Billion in 2024 and is expected to reach USD 25.20 Billion in 2025 and is expected to reach around USD 118.63 Billion by 2034, at a CAGR of 18.79% between 2025 and 2034. The key market players listed in the report with their sales, revenues and strategies are Amgen, Inc., Biogen Inc., Biomarin Pharmaceutical Inc., Bluebird Bio, Inc. (Celgene Corporation), Bristol-Myers Squibb Company, Freeline Therapeutics Ltd., Gene Biotherapeutics, Gilead Sciences, Inc., Horama S.A., JCR Pharmaceuticals Co. Ltd., Kolon TissueGene, Inc., MeiraGTx Limited, Novartis International AG, Orchard Therapeutics Plc., and Organogenesis, Inc, and others. Austin, TX, USA, June 25, 2025 (GLOBE NEWSWIRE) -- Custom Market Insights has published a new research report titled 'Cell and Gene Therapy Market Size, Trends and Insights By Therapy Type (Cell Theray, Gene Therapy), By Therapeutic Class (Cardiovascular Disease, Cancer, Genetic Disorder, Rare Diseases, Oncology, Hematology, Ophthalmology, Infectious Disease, Neurological Disorders, Others), By Delivery Method (In Vivo, Ex Vivo), By End-User (Hospitals, Cancer Care Centers, Others), and By Region - Global Industry Overview, Statistical Data, Competitive Analysis, Share, Outlook, and Forecast 2025–2034' in its research database. 'According to the latest research study, the demand of global Cell and Gene Therapy Market size & share was valued at approximately USD 21.23 Billion in 2024 and is expected to reach USD 25.20 Billion in 2025 and is expected to reach a value of around USD 118.63 Billion by 2034, at a compound annual growth rate (CAGR) of about 18.79% during the forecast period 2025 to 2034.' Click Here to Access a Free Sample Report of the Global Cell and Gene Therapy Market @ Overview According to industry experts at CMI, the implementation of new strategies and technologies by the manufacturers presents lucrative opportunities for players in the Cell and Gene Therapy Market during the forecast period. Furthermore, we expect the growing significance of organized retailing to drive the future growth of the market. Key Trends & Drivers Advancements in Gene Editing Technologies: The development of precise gene editing tools such as CRISPR-Cas9, TALENs, and zinc finger nucleases is reshaping the gene therapy market. These technologies help in the accurate fixing of mutations in the genetic material, along with reducing off-target effects and enhancing safety. We expect CRISPR to gain popularity due to its efficiency, cost-effectiveness, and versatility in treating various genetic disorders. With the evolution of these tools, more clinical programs are now involved in integrating them, including therapies for inherited diseases and certain cancers. Continuous innovations in editing precision, delivery systems, and regulatory oversight are catapulting gene editing to the forefront of gene therapy applications in the future and expanding its commercial scope. Gene therapy: is rapidly expanding into rare and orphan diseases, many of which lack established treatments. These conditions often tend to have a well-defined genetic cause, making them apt candidates for gene intervention. Regulatory incentives such as orphan drug designations, priority review, and extended marketing exclusivity provide more encouragement for development in this arena. Emerging therapies are targeting spinal muscular atrophy, Duchenne muscular dystrophy, and inherited retinal disorders, while inroads made by their success have contributed to the further increase in research. This trend is addressing several pressing unmet medical needs while also providing for quicker entry into the marketplace with comparatively less competition, thereby fueling the rapid growth of the gene therapy sector. Increasing Regulatory Support and Fast-Track Approvals: Increasingly, worldwide regulatory bodies such as the FDA and EMA are bestowing fast-track designations, breakthrough therapy statuses, and conditional approvals for promising gene therapies. These pathways are meant to fast-track development and review of treatments for serious or life-threatening illnesses. Such a regulatory change indicates growing confidence in gene therapy regarding safety and efficacy, as well as the urgency of putting new treatment modalities on the market. With more therapies entering the clinical success phase, regulatory agencies are now actively working with developers to update and revise the guidance on manufacturing, trial design, and post-market surveillance. Hence, a forward regulatory approach accelerates approvals and enhances investor confidence in the field. Growth in Strategic Partnerships and M&A Activity: The gene therapy market is currently witnessing an increase in strategic collaborations, licensing deals, mergers, and acquisitions between biotech startups and large pharma companies. The partnerships then translate into the commercialization of innovation by bringing together innovative research and development with the regulatory, manufacturing, and distribution capabilities of big pharma. The big players are essentially looking to pump life into their pipeline while the smaller players are getting capital infusion and technical know-how. The notable M&A activities give a similar indication of confidence in the long-term value of gene therapies. Therefore, it promotes the efficiency of R&D, speeds up the arrival of products to the market, and shapes a competitive landscape, which in turn helps drive the growth of the market and increase the availability of new proposed treatments. Request a Customized Copy of the Cell and Gene Therapy Market Report @ Innovations in Delivery Mechanisms: The successful gene therapy needs the efficient delivery of the genetic materials inside the target cells. The innovations in the delivery systems, like adeno-associated viruses, lentiviral vectors, lipid nanoparticles, and non-viral systems are ushering in better therapeutic outcomes and have fewer side effects. These delivery systems are being fine-tuned for specific tissues and diseases, thereby increasing precision while reducing immune responses to the vector. Better platforms also consider vector re-dosing, increased tissue distribution, and efficacy, along with more straightforward manufacturing. As we develop better delivery technologies, the newer ones can treat more types of conditions and keep patients safer, making it easier to use gene therapy widely and helping it gain acceptance in clinics. Increasing Investment and Funding Activities: As there has been a surge in the venture capital, private equity, and public market investments coming into the fold, gene therapy is becoming more promising for the research and commercialization. The existence of several high-profile IPOs, funding rounds, and government grants serves as proof of investor confidence in gene therapy and in its ability to bring about a kind of transformation. The finances allow companies to further investigate the R&D, conduct clinical trials, and upgrade manufacturing facilities. Furthermore, there are also public and philanthropic organizations supporting early-stage innovations. This source of funding empowers developers to explore a broader range of diseases, invest in innovative technologies, and aim for global market penetration. Continued funding is a requisite to keep the momentum going and to ensure the long-term sustainability of the gene therapy sector. Report Scope Feature of the Report Details Market Size in 2025 USD 25.20 Billion Projected Market Size in 2034 USD 118.63 Billion Market Size in 2024 USD 21.23 Billion CAGR Growth Rate 18.79% CAGR Base Year 2024 Forecast Period 2025-2034 Key Segment By Therapy Type, Therapeutic Class, Delivery Method, End-User and Region Report Coverage Revenue Estimation and Forecast, Company Profile, Competitive Landscape, Growth Factors and Recent Trends Regional Scope North America, Europe, Asia Pacific, Middle East & Africa, and South & Central America Buying Options Request tailored purchasing options to fulfil your requirements for research. (A free sample of the Cell and Gene Therapy report is available upon request; please contact us for more information.) Our Free Sample Report Consists of the following: The updated report for 2024 includes an Introduction, an Overview, and an in-depth industry analysis. We have included the COVID-19 Pandemic Outbreak Impact Analysis in the package. About 220+ Pages Research Report (Including Recent Research) Provide detailed chapter-by-chapter guidance on the Request. Updated Regional Analysis with a Graphical Representation of Size, Share, and Trends for the Year 2025 Includes We have updated the tables and figures. The most recent version of the report includes the Top Market Players, their Business Strategies, Sales Volume, and Revenue Analysis Custom Market Insights (CMI) research methodology (Please note that the sample of the Cell and Gene Therapy report has been modified to include the COVID-19 impact study prior to delivery.) Request a Customized Copy of the Cell and Gene Therapy Market Report @ SWOT Analysis Strengths: A key advantage of cell and gene therapies is that they can go beyond just treating symptoms to tackle the root causes of diseases, providing the exciting chance for a single treatment for conditions that were once thought to be untreatable. The CGT market is experiencing exponential growth, with projections consistently indicating continued rapid expansion. The CGT market is propelled by ground-breaking technological advancements that enhance both the precision and potential of therapies. Weakness: A significant weakness of the Cell and Gene Therapy market is the exorbitant cost associated with manufacturing these advanced therapies, which currently renders them financially inaccessible for many patients. Scaling the manufacturing of cell and gene therapies to meet increasing global demand presents a formidable challenge. The supply chain for cell and gene therapies is exceptionally intricate and highly vulnerable, primarily due to the delicate nature of the products and strict logistical requirements. Opportunities: The increasing number of people suffering from long-term illnesses like different types of cancer, heart diseases, and diabetes, as well as a rise in genetic disorders such as sickle cell anemia and cystic fibrosis, is a strong reason for the growing need for new treatments. Governments worldwide are increasingly recognizing the transformative potential of cell and gene therapies and are actively supporting their development through significant initiatives and funding. The development and adoption of value-based payment models represent a crucial opportunity to mitigate the primary threat of high upfront costs. Threats: The most immediate and significant threat to the Cell and Gene Therapy market stems from the exorbitant upfront costs of these therapies, which create substantial reimbursement hurdles. A considerable threat to the CGT market's sustained growth and broader adoption is the inherent uncertainty surrounding the long-term efficacy and durability of these novel therapies. The intellectual property (IP) landscape surrounding cell and gene therapies presents a complex and formidable barrier to competition, potentially limiting market access and perpetuating high costs. Request a Customized Copy of the Cell and Gene Therapy Market Report @ Key questions answered in this report: What is the size of the cellular and gene therapy market, and what is its expected growth rate? What are the primary driving factors that push the Cell and Gene Therapy market forward? What are the Cell and Gene Therapy Industry's top companies? What are the different categories that the Cell and Gene Therapy Market caters to? What will be the fastest-growing segment or region? In the value chain, what role do essential players play? What is the procedure for getting a free copy of the Cell and Gene Therapy market sample report and company profiles? Key Offerings: Market Share, Size & Forecast by Revenue | 2025−2034 Market Dynamics – Growth Drivers, Restraints, Investment Opportunities, and Leading Trends Market Segmentation – A detailed analysis by Types of Services, by End-User Services, and by regions Competitive Landscape – Top Key Vendors and Other Prominent Vendors Buy this Premium Cell and Gene Therapy Research Report | Fast Delivery Available - [220+ Pages] @ Regional Analysis The Cell and Gene Therapy Market is segmented into various regions, including North America, Europe, Asia-Pacific, and LAMEA. Here is a brief overview of each region: North America: North America dominates cell and gene therapy (CGT) markets due to strong health infrastructure, substantial R&D investments, and a supportive regulatory landscape. Leading biotech entities present and contributed to the creation and growth of excellent clinical trial networks that stimulate innovation and commercialization. The U.S. is a pivotal market for early adoption of therapies like CAR-T. Strong governmental support, acceptance by the patient populace, and insurance reimbursements act as factors that augment market growth. The FDA's accelerated approval pathway and breakthrough therapy designations also allow the availability of treatments years before commercialization. Europe: Cell and gene therapy market in Europe is witnessing rapid growth with increasing investments in biotechnology and favorable regulatory initiatives such as the PRIME scheme by the European Medicines Agency. Countries such as Germany, the UK, and France are flower centers of research and clinical trials augmented by strong collaborative partnerships between public and private organizations. The rising incidence of chronic and rare diseases is further driving market demand. However, heterogeneous healthcare systems and reimbursement procedures act as hurdles in market access. Several initiatives have been set to harmonize the regulatory framework and set up an efficient infrastructure for manufacturing. Asia-Pacific: Considered an emerging and fast-growing market for cell and gene therapies, this region sees rising healthcare expenditure, development of biotechnology sectors, and an increasing prevalence of various diseases as high growth factors. Besides China, Japan has invested heavily in CGT research, clinical trials, and manufacturing setups; South Korea, too, is gradually forging ahead. Regulatory bodies have increasingly adapted to facilitate faster approvals, while growing awareness among clinicians and patients is also contributing to market growth. Although infrastructural and reimbursement constraints exist in some pockets, expanding government schemes and international collaborations further bolster the market growth. LAMEA: The LAMEA cell and gene therapy market is at an early stage but is expected to grow at a significant rate owing to the increasing burden of diseases along with the improving healthcare infrastructure. Latin America, the Middle East, and Africa have witnessed heightened activity in biotechnology and clinical research but remain limited in market penetration due to regulatory hitches, absence of specialized facilities, and reimbursement issues. The increasing partnership with the international biotech players along with the increasing initiatives from the government for better healthcare accessibility is expected to propel the market growth. Enhancements in awareness and infrastructure will establish LAMEA as a promising region for CGT, particularly in addressing unmet medical needs related to rare and genetic diseases. Request a Customized Copy of the Cell and Gene Therapy Market Report @ (We customized your report to meet your specific research requirements. Inquire with our sales team about customizing your report.) Still, Looking for More Information? Do you want data for inclusion in magazines, case studies, research papers, or media? Email Directly Here with Detail Information: support@ Browse the full 'Cell and Gene Therapy Market Size, Trends and Insights By Therapy Type (Cell Theray, Gene Therapy), By Therapeutic Class (Cardiovascular Disease, Cancer, Genetic Disorder, Rare Diseases, Oncology, Hematology, Ophthalmology, Infectious Disease, Neurological Disorders, Others), By Delivery Method (In Vivo, Ex Vivo), By End-User (Hospitals, Cancer Care Centers, Others), and By Region - Global Industry Overview, Statistical Data, Competitive Analysis, Share, Outlook, and Forecast 2025–2034' Report at List of the prominent players in the Cell and Gene Therapy Market: Amgen Inc. Biogen Inc. Biomarin Pharmaceutical Inc. Bluebird Bio Inc. (Celgene Corporation) Bristol-Myers Squibb Company Freeline Therapeutics Ltd. Gene Biotherapeutics Gilead Sciences Inc. Horama S.A. JCR Pharmaceuticals Co. Ltd. Kolon TissueGene Inc. MeiraGTx Limited Novartis International AG Orchard Therapeutics Plc. Organogenesis Inc. Others Click Here to Access a Free Sample Report of the Global Cell and Gene Therapy Market @ Spectacular Deals Comprehensive coverage Maximum number of market tables and figures We offer a subscription-based option. Best price guarantee We offer free 35% or 60 hours of customization. We also offer free post-sale service assistance. You will receive a 25% discount on your subsequent purchases. Service guarantees are available. The author will create a customized market brief for you. Browse More Related Reports: Advanced Genomics Market: Advanced Genomics Market Size, Trends and Insights By Offering (Products, Services), By Technology (Sequencing, PCR, Gene Editing, Flow Cytometry, Microarrays, In Situ Hybridization), By Application (Diagnostics, Drug Discovery and Development, Precision Medicine, Agriculture), By End-user (Hospitals and Clinics, Research Centers, Pharmaceutical and Biotechnology Companies), and By Region - Global Industry Overview, Statistical Data, Competitive Analysis, Share, Outlook, and Forecast 2025 – 2034 Battery-Free Implants Market: Battery-Free Implants Market Size, Trends and Insights By Product Type (Neural Implants, Cardiac Implants , Cochlear Implants, Orthopedic Implants, Others), By Technology (Energy Harvesting, Wireless Power Transfer, RFID/NFC-based Systems), By End User (Hospitals & Clinics, Ambulatory Surgical Centers, Research Institutions, Specialty Clinics), and By Region - Global Industry Overview, Statistical Data, Competitive Analysis, Share, Outlook, and Forecast 2025–2034 Duchenne Muscular Dystrophy Drugs Market: Duchenne Muscular Dystrophy Drugs Market Size, Trends and Insights By Drug Type (Exon skipping drugs, Corticosteroids, Gene therapy, Other drug types), By Route of Administration (Oral, Injectable), and By Region - Global Industry Overview, Statistical Data, Competitive Analysis, Share, Outlook, and Forecast 2025 – 2034 Psychiatric Digital Biomarkers Market: Psychiatric Digital Biomarkers Market Size, Trends and Insights By Type (Wearable, Mobile based Applications, Sensors, Other Type), By Clinical Practice (Diagnostic Psychiatric Digital Biomarkers, Monitoring Psychiatric Digital Biomarkers, Predictive and Prognostic Psychiatric Digital Biomarkers, Other Clinical Practice), By End Use (Healthcare Companies, Healthcare Providers, Payers, Other End Use), and By Region - Global Industry Overview, Statistical Data, Competitive Analysis, Share, Outlook, and Forecast 2025–2034 Electrophysiology Devices Market: Electrophysiology Devices Market Size, Trends and Insights By Type (Ablation Catheters, Diagnostic Catheters, Mapping System, Accessories, Others), By Application (Atrial Fibrillation, Supraventricular Tachycardia (SVT), Ventricular Tachycardia, Others), By End User (Hospitals & ASCs, Specialty Clinics & Diagnostic Centers), and By Region - Global Industry Overview, Statistical Data, Competitive Analysis, Share, Outlook, and Forecast 2025 – 2034 Vitreous Tamponades Market: Vitreous Tamponades Market Size, Trends and Insights By Product Type (Gaseous Tamponades, Liquid Tamponades, Silicone Oil, Perchloroethane, Others), By Application (Retinal Detachment, Macular Hole, Endophthalmis, Intraocular Tumours, Vitreous Haemorrhage, Others), By End User (Hospitals, Ophthalmology Clinics), and By Region - Global Industry Overview, Statistical Data, Competitive Analysis, Share, Outlook, and Forecast 2025 – 2034 Heart Valve Devices Market: Heart Valve Devices Market Size, Trends and Insights By Product Type (Mechanical Heart Valves, Biological Heart Valves, Transcatheter Heart Valves), By Treatment (Valve Repair, Valve Replacement), By End-User (Hospitals & Clinics, Ambulatory Surgical Centers, Cardiac Centers, Others), and By Region - Global Industry Overview, Statistical Data, Competitive Analysis, Share, Outlook, and Forecast 2025 – 2034 Infusion Therapy Market: Infusion Therapy Market Size, Trends and Insights By Product (Infusion Pump, Intravenous Sets, IV Cannulas, Needleless Connectors), By Application (Anti-infective, Hydration Therapy, Chemotherapy, Enteral Nutrition, Parenteral Nutrition, Specialty Pharmaceuticals, Other), By End-user (Hospitals, Ambulatory Surgical Centers, Clinics, Homecare Settings), and By Region - Global Industry Overview, Statistical Data, Competitive Analysis, Share, Outlook, and Forecast 2025 – 2034 The We have segmented the Cell and Gene Therapy Market as follows: By Therapy Type Cell Theray Gene Therapy By Therapeutic Class Cardiovascular Disease Cancer Genetic Disorder Rare Diseases Oncology Hematology Ophthalmology Infectious Disease Neurological Disorders Others By Delivery Method In Vivo Ex Vivo By End-User Hospitals Cancer Care Centers Others Click Here to Get a Free Sample Report of the Global Cell and Gene Therapy Market @ Regional Coverage: North America U.S. Canada Mexico Rest of North America Europe Germany France U.K. Russia Italy Spain Netherlands Rest of Europe Asia Pacific China Japan India New Zealand Australia South Korea Taiwan Rest of Asia Pacific The Middle East & Africa Saudi Arabia UAE Egypt Kuwait South Africa Rest of the Middle East & Africa Latin America Brazil Argentina Rest of Latin America This cell and gene therapy market research and analysis report contains answers to the following questions: Which Trends Are Causing These Developments? Who Are the Global Key Players in This Cell and Gene Therapy Market? What are the company profiles, product information, and contact details for these key players? What Was the Global Market Status of the Cell and Gene Therapy Market? What Was the Capacity, Production Value, Cost and PROFIT of the Cell and Gene Therapy markets? What Is the Current Market Status of the Cell and Gene Therapy industries? What's the market's competition in this industry, both company-wise and country-wise? What's the Market Analysis of Cell and Gene Therapy Market by Considering Applications and Types? What Are Projections of the Global Cell and Gene Therapy Industry Considering Capacity, Production, and Production Value? What Will Be the estimate of Cost and Profit? What Will Be Market Share, Supply, and Consumption? What about imports and exports? What Is Cell and Gene Therapy Market Chain Analysis by Upstream Raw Materials and Downstream Industry? What Is the Economic Impact On Cell and Gene Therapy Industry? What are Global Macroeconomic Environment Analysis Results? What Are Global Macroeconomic Environment Development Trends? What Are Market Dynamics of Cell and Gene Therapy Market? What Are Challenges and Opportunities? What Should Be Entry Strategies, Countermeasures to Economic Impact, and Marketing Channels for Cell and Gene Therapy Industry? Click Here to Access a Free Sample Report of the Global Cell and Gene Therapy Market @ Reasons to Purchase Cell and Gene Therapy Market Report Cell and Gene Therapy Market Report provides qualitative and quantitative analysis of the market based on segmentation involving economic and non-economic factors. Cell and Gene Therapy Market report outlines market value (USD) data for each segment and sub-segment. This report indicates the region and segment expected to witness the fastest growth and dominate the market. Cell and Gene Therapy Market Analysis by geography highlights the consumption of the product/service in the region and indicates the factors affecting the market within each region. The competitive landscape incorporates the market ranking of the major players, along with new service/product launches, partnerships, business expansions, and acquisitions in the past five years of companies profiled. The report includes extensive company profiles, which include company overviews, insights, product benchmarking, and SWOT analyses for the major market players. The Industry's current and future market outlook concerning recent developments (which involve growth opportunities and drivers as well as challenges and restraints of both emerging and developed regions). Cell and Gene Therapy Market Includes in-depth market analysis from various perspectives through Porter's five forces analysis and offers context for the market through Value Chain. Reasons for the Research Report The study provides a thorough overview of the global Cell and Gene Therapy market. Compare your performance to that of the market as a whole. Aim to maintain competitiveness while innovations from established leaders drive market growth. Buy this Premium Cell and Gene Therapy Research Report | Fast Delivery Available - [220+ Pages] @ What does the report include? Drivers, restrictions, and opportunities are among the qualitative elements covered in the worldwide Cell and Gene Therapy market analysis. The competitive environment of current and potential participants in the Cell and Gene Therapy market is covered in the report, as well as those companies' strategic product development ambitions. According to the component, application, and industry vertical, this study analyzes the market qualitatively and quantitatively. Additionally, the report offers comparable data for the important regions. We have provided actual market sizes and forecasts for each of the aforementioned segments. Who should buy this report? Participants and stakeholders in the worldwide Cell and Gene Therapy market should find this report useful. The research will be useful to all market participants in the Cell and Gene Therapy industry. Managers in the Cell and Gene Therapy sector are interested in publishing up-to-date and projected data about the worldwide Cell and Gene Therapy market. Governmental agencies, regulatory bodies, decision-makers, and organizations want to invest in Cell and Gene Therapy products' market trends. Market insights are sought by analysts, researchers, educators, strategy managers, and government organizations to develop plans. Request a Customized Copy of the Cell and Gene Therapy Market Report @ About Custom Market Insights: Custom Market Insights is a market research and advisory company delivering business insights and market research reports to large, small, and medium-scale enterprises. We assist clients with strategies and business policies and regularly work toward achieving sustainable growth in their respective domains. CMI offers a comprehensive solution, from data collection to investment advice. Our company's expert analysis digs out essential factors that help us understand the significance and impact of market dynamics. The professional experts utilize client insights to inform strategies for estimating future declines, forecasting opportunities for growth, and conducting consumer surveys. Follow Us: LinkedIn | Twitter | Facebook | YouTube Contact Us: Joel John CMI Consulting LLC 1333, 701 Tillery Street Unit 12, Austin, TX, Travis, US, 78702 USA: +1 737-734-2707 India: +91 20 46022736 Email: support@ Web: Blog: Blog: Blog: Blog: Buy this Premium Cell and Gene Therapy Research Report | Fast Delivery Available - [220+ Pages] @ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
